Skip to main content
. 2018 Aug 27;7(11):e1507668. doi: 10.1080/2162402X.2018.1507668

Figure 5.

Figure 5.

MHC-II and CD86 protein levels are unchanged by pre-operative Dex-treatment. Quantitative image analysis of FFPE samples used in Nanostring analysis (Table 1) reveal no difference in (A) HLA-DR, DP, DQ or (B) CD86 protein expression. Line indicates median. (C) Immunofluorescent staining for HLA-DR, DP, DQ (green) and CD163 (red, top image) or GFAP (red, bottom image) show that MHC-II is restricted to CD163+ cells and is not expressed by GFAP+ tumor cells or astrocytes.